Skip to content
International Academy for Clinical Hematology (IACH) Logo
  • About
    • Mission
    • ExComm & Bylaws
    • Topics
    • Membership
    • Founders
    • Conflict of Interest Policy
    • Clinical Hematology International
    • IACH Supporters
    • Terms of Service
    • Contact
  • Meetings
    • Controversies in Multiple Myeloma (COMy)
    • Controversies in MDS and AML (COMydAL)
    • Controversies in Lymphoma (COLYM)
    • MPNControversies & Debates (MPN Co&D)
    • Annual Meeting of the IACH
    • Summit on Immunotherapy and Cellular Therapy in Cancer (ICTC)
  • Webinars
    • Webinars
    • Junior Club
    • Journal Club
    • Post-Cong. webinars
    • Special webinars
  • Nurses
  • Special Events
    • IACH Giants
    • IACH CAR-T News
    • The Innovation and R&D Podium
  • Podcasts
  • Pharmacists
  • Patients
  • News of the Week

April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy

  1. Home
  2. All
  3. April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy
Previous Next

April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy

By efrat|2024-04-08T07:25:13+00:00April 9th, 2024|All|Comments Off on April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: efrat

Related Posts

September 13th 2024- Prof. Martin Ellis- Differential Effects of Itacitinib, Fedratinib, and Ruxolitinib in Mouse Models of Hemophagocytic Lymphohistiocytosis

September 13th 2024- Prof. Martin Ellis- Differential Effects of Itacitinib, Fedratinib, and Ruxolitinib in Mouse Models of Hemophagocytic Lymphohistiocytosis

September 2nd 2024- Prof. Mark Litzow- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

September 2nd 2024- Prof. Mark Litzow- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

August 26th 2024- Prof. Olaf Penack- How risky is a second allogeneic stem cell transplantation?

August 26th 2024- Prof. Olaf Penack- How risky is a second allogeneic stem cell transplantation?

July 22nd 2024- Dr. Kai Rejeski- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

July 22nd 2024- Dr. Kai Rejeski- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

July 16th 2024- Prof. Madhav Dhodapkar- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

July 16th 2024- Prof. Madhav Dhodapkar- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

About

The IACH, founded by an international group of physicians whose focus is to promote good clinical practice in the field of clinical hematology, is registered in England (Number: 14200227) under the Companies Act 2006.

In collaboration with:

Contact

International Academy for Clinical Hematology (IACH)
35 Ballards Lane
London N3 1XW
United-Kingdom
info@clinical-hematology.org
+44 203 291 1603
IACH on Twitter
IACH on LinkedIn

Copyright © 2022 International Academy for Clinical Hematology | All Rights Reserved
Page load link
Go to Top